CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage

Adhesion between the CD44s receptor and hyaluronic acid plays an important role in cell migration, tumour growth and progression. Although the alternative splicing of CD44 variant exons represents the principal regulatory mechanism of CD44-mediated functions, CD44v spliced variants are scantily expressed in melanoma cells. For this reason, we have investigated the possibility that post-translational modifications of the CD44 standard receptor could play a pivotal role in regulating CD44-mediated functions in melanoma. Using metabolic inhibitors of N- and O-glycosylation, as well as melanoma transfectants expressing CD44s O-glycosylation site-specific mutants, we performed structural and functional analysis of N- and O-deglycosylated CD44s molecules expressed in melanoma cells. We discovered that complete N- and O-glycosylation is not required by CD44s to be correctly expressed on the melanoma cell surface. Indeed, variably glycosylated and functionally different CD44s molecules were constitutively expressed in primary and metastatic lesions. Furthermore, we observed that changes in N- and O-glycosylation of CD44s could modulate its cleavage. In fact, spontaneous CD44s shedding was dependent on the presence of partial or complete O-glycosylation of four serine–glycine motifs localized in the membrane-proximal CD44 ectodomain. Mutation of these serine residues, as well as an extensive metabolic O-deglycosylation, strongly impaired spontaneous CD44 shedding. Furthermore, an O-glycosylation-independent mechanism of CD44 cleavage has been identified. This alternative mechanism of receptor cleavage is phorbol 12-myristate-13-acetate (PMA) inducible, mediated by metalloproteinase and requires the presence of N-linked sugar residues. Our findings demonstrate that the post-translational modification of CD44s represents the principal regulatory mechanism of CD44s-mediated functions in melanoma.

[1]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[2]  M. Nakao,et al.  CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration , 1999, Oncogene.

[3]  I. Stamenkovic,et al.  Glycosylation Provides Both Stimulatory and Inhibitory Effects on Cell Surface and Soluble CD44 Binding to Hyaluronan , 1998, The Journal of cell biology.

[4]  I. Stamenkovic,et al.  Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function , 1997, The Journal of experimental medicine.

[5]  D. Cheresh,et al.  Integrins and cancer. , 1996, Current opinion in cell biology.

[6]  E. Bröcker,et al.  Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. , 1996, Journal of cell science.

[7]  I. Stamenkovic,et al.  Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan , 1996, The Journal of cell biology.

[8]  K. Bennett,et al.  Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons , 1995, The Journal of cell biology.

[9]  A. Perschl,et al.  Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation , 1995, The Journal of experimental medicine.

[10]  K. Oritani,et al.  Glycosylation of CD44 negatively regulates its recognition of hyaluronan , 1995, The Journal of experimental medicine.

[11]  E. Danen,et al.  Glycoconjugate profile and cd44 expression in human melanoma cell lines with different metastatic capacity , 1995, International journal of cancer.

[12]  K. Bennett,et al.  Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. , 1995, Journal of cell science.

[13]  K. Bennett,et al.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor , 1995, The Journal of cell biology.

[14]  M. Culty,et al.  Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potential , 1994, Journal of cellular physiology.

[15]  I. Stamenkovic,et al.  Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development , 1994, The Journal of experimental medicine.

[16]  E. Danen,et al.  Emergence of α5β1 fibronectin‐ and αvβ3 vitronectin‐receptor expression in melanocytic tumour progression , 1994 .

[17]  Mark S. Anderson,et al.  The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44 , 1993, Cell.

[18]  I. Stamenkovic,et al.  Identification of hyaluronic acid binding sites in the extracellular domain of CD44 , 1993, Journal of Cell Biology.

[19]  A. Bartolazzi,et al.  Integrin expression in cutaneous malignant melanoma: Association of the α3/β1 heterodimer with tumor progression , 1993 .

[20]  P. Herrlich,et al.  Prevention of tumor metastasis formation by anti-variant CD44 , 1993, The Journal of experimental medicine.

[21]  I. Stamenkovic,et al.  CD44H regulates tumor cell migration on hyaluronate-coated substrate , 1992, The Journal of cell biology.

[22]  P. Herrlich,et al.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44. , 1992, Science.

[23]  J. Bell,et al.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. , 1992, The Journal of biological chemistry.

[24]  I. Stamenkovic,et al.  Distinct effects of two CD44 isoforms on tumor growth in vivo , 1991, The Journal of experimental medicine.

[25]  D. Anstee,et al.  New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. , 1991, Immunology.

[26]  P. Natali,et al.  Tumor progression in human malignant melanoma is associated with changes in α6/β1 laminin receptor , 1991 .

[27]  S. Jalkanen,et al.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. , 1991, The Journal of clinical investigation.

[28]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[29]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[30]  E. Ruoslahti,et al.  Analysis of glycosaminoglycan substitution in decorin by site-directed mutagenesis. , 1990, The Journal of biological chemistry.

[31]  B. Haynes,et al.  Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. , 1990, Journal of immunology.

[32]  M. Telen,et al.  CD44--a molecule involved in leukocyte adherence and T-cell activation. , 1989, Immunology today.

[33]  B. Caillou,et al.  CD44 contributes to T cell activation. , 1989, Journal of immunology.

[34]  Brian Seed,et al.  A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family , 1989, Cell.

[35]  I. Stamenkovic,et al.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.

[36]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.